Medical technology company SciBase Holding AB (STO: SCIB) announced on Monday that it has launched the Nevisense Self-Pay Program in the US, enabling patients to access its skin cancer detection test outside traditional insurance coverage. Several dermatology practices across the country have already adopted the initiative, with further expansion planned.

Growing clinical emphasis on early melanoma detection and evolving care standards are driving strong demand for Nevisense from both patients and dermatologists. The self-pay model allows clinicians to integrate Nevisense into diagnostic workflows sooner, ensuring timely testing for at-risk patients regardless of insurance status.

Nevisense offers a point-of-care solution that enhances clinical decision-making and supports earlier melanoma detection, improving patient outcomes and reducing healthcare system burdens.

SciBase develops, manufactures and markets Nevisense, a platform combining AI and advanced electrical impedance spectroscopy technology, based on over 20 years of research at Karolinska Institute. The company focuses on improving skin health management through early detection and prevention.